Kiora Pharmaceuticals Reports Preclinical Data for KIO-300 in Epilepsy Model
On June 18, 2026, Kiora Pharmaceuticals announced preclinical data for KIO-300, its novel ion channel modulator, demonstrating significant suppression of seizure-associated activity in an ex vivo temporal lobe epilepsy (TLE) model. The data, presented at the Epilepsy Foundation Pipeline Conference, showed that KIO-300 produced sustained suppression of epileptiform activity in mouse hippocampal CA1 slices. Statistically significant inhibition of spontaneous event frequency began 42 minutes after treatment (p < 0.0001), and the suppressive effect persisted through the washout period, suggesting prolonged neural tissue retention. Importantly, KIO-300 did not impair general electrical transmission, indicating specificity for abnormal activity. KIO-300 is the active pharmaceutical ingredient in KIO-301, Kioraβs Phase 2 candidate for vision restoration in Retinitis Pigmentosa. These findings suggest potential therapeutic utility for Kiora's platform in neurological disorders beyond ophthalmology, where the company retains full development and commercialization rights. Future R&D will focus on targeted delivery and molecular modifications for epilepsy.